Curevo
Curevo is a Seattle-based biotech startup focused on developing a vaccine against shingles, operating in the biotechnology and...
Facts
- HQ
- Bothell, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2017
- Employees
- 34
- Stage
- Clinical-stage
- Total raised
- $110M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $42.4M · Mar 2025 SEC Form D
Recent coverage
Front-page news, podcasts and videos about Curevo
Curevo Raises $110M Series B to Advance Shingles Vaccine Amid GSK Competition, Adds Former GSK and Moderna Execs to Board
Seattle biotech startup Curevo raised $110 million in a Series B round to advance Phase 2 trials of its shingles vaccine amezosvatein, competing with GlaxoSmithKline's Shingrix. The company added biotech veterans, including former GSK and Moderna executives, to its board to support development.
People
-
George Simeon Former Chairman & Chief Executive Officer
